Author response to Colle et al
The event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, w...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/6/e003138.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846172946275500032 |
|---|---|
| author | Giovanni Fucà Filippo Pietrantonio Francesca Corti |
| author_facet | Giovanni Fucà Filippo Pietrantonio Francesca Corti |
| author_sort | Giovanni Fucà |
| collection | DOAJ |
| description | The event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, with early assessments being associated with higher incidence. Such dynamics should be considered when interpreting the efficacy of treatment. |
| format | Article |
| id | doaj-art-4541f8066c2d4353b4de9fdeee044e9e |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2021-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-4541f8066c2d4353b4de9fdeee044e9e2024-11-08T20:35:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-06-019610.1136/jitc-2021-003138Author response to Colle et alGiovanni Fucà0Filippo Pietrantonio1Francesca Corti21 Department of Gynecologic Oncology, Humanitas San Pio X, Milan, ItalyMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyThe event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, with early assessments being associated with higher incidence. Such dynamics should be considered when interpreting the efficacy of treatment.https://jitc.bmj.com/content/9/6/e003138.full |
| spellingShingle | Giovanni Fucà Filippo Pietrantonio Francesca Corti Author response to Colle et al Journal for ImmunoTherapy of Cancer |
| title | Author response to Colle et al |
| title_full | Author response to Colle et al |
| title_fullStr | Author response to Colle et al |
| title_full_unstemmed | Author response to Colle et al |
| title_short | Author response to Colle et al |
| title_sort | author response to colle et al |
| url | https://jitc.bmj.com/content/9/6/e003138.full |
| work_keys_str_mv | AT giovannifuca authorresponsetocolleetal AT filippopietrantonio authorresponsetocolleetal AT francescacorti authorresponsetocolleetal |